EQ-5D health utilities: exploring ways to improve upon responsiveness in psoriasis

Relationship between psoriasis severity, clinical symptoms, quality of life and work productivity among patients in the USA

(2016) N. J. Korman et al.   CLINICAL AND EXPERIMENTAL DERMATOLOGY

Clinical meaningfulness of complete skin clearance in psoriasis

(2016) Bruce Strober et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

(2016) Kenneth B. Gordon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

(2015) Christopher E M Griffiths et al.   LANCET

Total skin clearance results in improvements in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasis

(2014) Hema N. Viswanathan et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Patient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical setting

(2014) Junko Takeshita et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

(2014) Richard G. Langley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Switch to Biological Agent in Psoriasis Significantly Improved Clinical and Patient-Reported Outcomes in Real-World Practice

(2013) Jenny M. Norlin et al.   DERMATOLOGY

Development of a Disease-Specific Version of the EQ-5D-5L for Use in Patients Suffering from Psoriasis: Lessons Learned from a Feasibility Study in the UK

(2013) Paul Swinburn et al.   VALUE IN HEALTH

Quality of Life and Work Productivity Impairment among Psoriasis Patients: Findings from the National Psoriasis Foundation Survey Data 2003–2011

(2012) April W. Armstrong et al.   PLoS One

Interim Scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L Value Sets

(2012) Ben van Hout et al.   VALUE IN HEALTH

Analysis of three outcome measures in moderate to severe psoriasis: a registry-based study of 2450 patients

(2011) J.M. Norlin et al.   BRITISH JOURNAL OF DERMATOLOGY

Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)

(2011) M. Herdman et al.   QUALITY OF LIFE RESEARCH

PSS17 IMPACT OF ADALIMUMAB ON QUALITY OF LIFE AND DEPRESSION IN PSORIASIS PATIENTS: RESULTS FROM PRIDE

(2011) D Guh et al.   VALUE IN HEALTH

What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature

(2010) V Bronsard et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Once-Weekly Administration of Etanercept 50 mg Improves Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis

(2009) Kristian Reich et al.   DERMATOLOGY